Dr. Nikolaos Papanikolaou served as the Scientific Coordinator in the ProCAncer-I project, funded by the European Commission. His role involves overseeing the technical development of an AI platform integrating imaging data and predictive models to enhance precision care in prostate cancer. He also contributes to the EUCAIM project as a scientific advisor and AI technical expert. Furthermore, Dr. Papanikolaou is a founding member of the FUTURE-AI consortium, contributing significantly to the development of international guidelines for the safe and effective integration of AI in healthcare, recently published in BMJ.

At the forefront of oncologic imaging, his tenure at Champalimaud Foundation has been dedicated to refining radiomic signatures to revolutionize cancer diagnosis and treatment. The mission at Champalimaud, a beacon of biomedical research, aligns perfectly with his goal to harness the power of advanced medical imaging for better patient outcomes. Collaboratively, Dr. Papanikolaou's team has made significant strides in promoting MRI biomarkers in oncology.

Parallel to his work at Champalimaud, he has been leading machine learning imaging initiatives at The Royal Marsden NHS Foundation Trust, integrating artificial intelligence to enhance imaging interpretation. The dual roles have honed his expertise in applying AI to medical imaging, a skill underscored by multiple honors and certifications. Leveraging this, alongside his proficiency in radiomics and machine learning, his team aspires to set new standards in cancer care.